Ask AI
ProCE Banner Activity

PURPOSE 1 Substudy: Efficacy, Safety, and PK of Lenacapavir for PrEP in Pregnant and Lactating People

Conference Coverage
Slideset

In the phase III PURPOSE 1 study in South Africa and Uganda, twice-yearly subcutaneous lenacapavir for PrEP in pregnant and lactating people was found to be safe, effective, and well tolerated.

Released: July 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner